Cyril Varughese, DO
Advanced Heart Failure and Transplant Cardiology · Fort Worth, TXNPI 1770710543
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,900 of the $36,147 with a category attached, or 74.4%. AstraZeneca accounts for 77.4% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $9,649 and has fallen 90.4% since, to $930 in 2025.
Across 312 payments — averaging $115.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$28K
- Abiomed$2K
- Novartis$1K
- Abbott$1K
- Actelion Pharmaceuticals US, Inc.$731
- Medtronic$637
- plus $3K from 23 others
Across 1 payment — averaging $70.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$70
What the payments were for
- Speaking & faculty fees$26,90074%
- Travel & lodging$1550%
- Food & beverage$9,04725%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $27,992 |
| Abiomed | 15 | $1,621 |
| Novartis | 61 | $1,028 |
| Abbott | 37 | $1,024 |
| Actelion Pharmaceuticals US, Inc. | 28 | $731 |
| Medtronic | 7 | $637 |
| Pfizer | 38 | $613 |
| Cvrx, Inc. | 8 | $608 |
| E.r. Squibb & Sons, L.L.C. | 13 | $240 |
| Heartflow, Inc. | 3 | $226 |
| Getinge USA Sales, LLC | 3 | $202 |
| Amgen | 11 | $187 |
| Alnylam Pharmaceuticals Inc. | 3 | $148 |
| Impulse Dynamics (USA) Inc. | 1 | $144 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $136 |
| Boston Scientific | 2 | $92 |
| Inspire Medical Systems, Inc. | 2 | $83 |
| Sanofi-aventis U.S. LLC | 5 | $75 |
| Boehringer Ingelheim | 4 | $65 |
| United Therapeutics Corporation | 3 | $51 |
| Amarin Pharma, Inc. | 3 | $42 |
| Edwards Lifesciences | 1 | $34 |
| EBR Systems, Inc. | 1 | $31 |
| Atricure, Inc. | 2 | $31 |
| Recor Medical Inc | 2 | $28 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $23 |
| Novo Nordisk | 1 | $23 |
| Johnson & Johnson | 2 | $20 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$27,497
- Impella$1,181
- Barostim Neo System$513
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$443
- OPTIMIZER$288
- Micra$147
- Abre$139
- VYNDAQEL$115
- COREVALVE EVOLUT R$111
- ONYX FRONTIER$103
How this compares
$36,147 in reported general payments places this provider in the 70th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 96 | $1,211,229 |
| UptraviSelexipag | 34 | $764,747 |
| EliquisApixaban | 393 | $326,768 |
| EntrestoSacubitril/Valsartan | 225 | $201,934 |
| FarxigaDapagliflozin Propanediol | 133 | $98,911 |
| JardianceEmpagliflozin | 86 | $78,144 |
| XareltoRivaroxaban | 51 | $49,670 |
| Tadalafil | 39 | $44,379 |
| Ambrisentan | 17 | $37,348 |
| CorlanorIvabradine Hcl | 22 | $16,533 |
| Repatha SureclickEvolocumab | 12 | $15,505 |
| Ranolazine ErRanolazine | 111 | $6,440 |
| Icosapent Ethyl | 11 | $5,881 |
| Potassium Chloride | 348 | $5,862 |
| Valsartan | 157 | $4,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $731 | $1,975,976130 claims |
| PfizerEliquis | $613 | $326,768393 claims |
| NovartisEntresto | $1,028 | $201,934225 claims |
| AstraZenecaFarxiga | $27,992 | $98,911133 claims |
| Boehringer IngelheimJardiance | $65 | $78,14486 claims |
| Johnson & JohnsonXarelto | $20 | $49,67051 claims |
| AmgenCorlanor | $187 | $16,53322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Fort Worth
- Alpesh AminFort Worth$3K
- Robert GottliebDallas$717K
- Albert HicksTemple$613K
- Allen AndersonSan Antonio$413K
- Martin BerkDallas$379K
- Aasim AfzalPlano$336K
- Kunjan BhattAustin$324K
- Barry TrachtenbergHouston$306K
- Shelley HallDallas$254K
- Arvind BhimarajHouston$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.